DISCO Pharmaceuticals (“DISCO”) announced a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel A...
DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undrugg...
Developing effective drug formulations remains a major challenge for biopharma companies, particularly for molecules with poor solubility or complex releas...
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up ...
iDEL Therapeutics announced that it has entered into a research collaboration with Daiichi Sankyo (TSE: 4568) to utilize iDEL’s synthetic shuttl...
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received ...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered ...
ExoCordOA, a five-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clin...
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, announced that it has received a Direct-to-Phase II Small Business Innov...
Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President Kos Biotechnology Partners ("Kos"), a global ...
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42%...
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, softwa...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for t...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced that it has received full regulato...
© 2026 Biopharma Boardroom. All Rights Reserved.